Solvonis Therapeutics PLC
SVNS
Company Profile
Business description
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.
Contact
Eccleston Yards
25 Eccleston Place
LondonSW1W 9NF
GBRT: +44 7795430246
Sector
Industrials
Stock type
Sensitive
Industry
Specialty Industrial Machinery
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.30 | 0.40 | -0.00% |
| CAC 40 | 7,908.74 | 53.65 | -0.67% |
| DAX 40 | 22,921.59 | 246.49 | -1.06% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,348.79 | 87.50 | -0.84% |
| HKSE | 25,831.03 | 714.50 | 2.84% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 56,078.83 | 2,649.27 | 4.96% |
| NZX 50 Index | 13,267.85 | 198.19 | 1.52% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,955.90 | 16.90 | -0.19% |
| SSE Composite Index | 3,960.74 | 70.57 | 1.81% |